10 Best Performing Pharma Stocks in 2025

3. Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

1-Year Performance: 72.78%

Number of Hedge Fund Holders: 29

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is one of the best performing pharma stocks in 2025. On January 7, Truist raised the price target on Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) to $15 from $14 while maintaining a Buy rating. The firm sees the affordable medicines theme staying attractive in 2026.

In a separate development, Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) and mAbxience announced on December 22 that the U.S. Food and Drug Administration approved its Biologics Licensing Applications for Boncresa™, a biosimilar referencing Prolia®, and Oziltus™, a biosimilar referencing XGEVA®. Denosumab is a monoclonal antibody widely used across oncology and osteoporosis-related conditions and is known to inhibit bone resorption. Amneal Pharmaceuticals, Inc.’s (NASDAQ:AMRX) partnership with mAbxience entails that the former holds exclusive U.S. commercialization rights while the latter is responsible for manufacturing and development.

Chirag and Chintu Patel, Co-Chief Executive Officers of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX), stated that the addition of  two denosumab biosimilars has expanded the company’s portfolio to five commercial biosimilars, bolstering its position in the rapidly developing domain. Management views biosimilars as a considerable long-term growth vector in the company’s Affordable Medicines segment.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is a medicine company that provides pharmaceuticals. The company’s product portfolio encompasses biosciences, specialty, generics, and product catalog. Its operations are divided into the Generics, Specialty, and AvKARE segments.